First passengers leave HV Hondius amid suspected hantavirus concerns in Tenerife

The first passengers from the MV Hondius depart for Tenerife Airport aboard a Spanish Military Emergency Unit bus, escorted by a member of Spainâs External Health Service. (Photo by Andres Gutierrez/Anadolu via Getty Images)

Investors really want Moderna to whip up a hantavirus vaccine

The company told Bloomberg it is in the early stages of researching vaccines to protect against hantaviruses.

J. Edward Moreno

Moderna is soaring on hopes that it may be able to produce a vaccine to protect against hantavirus, which has killed three people and infected at least six others on a cruise ship crossing the Atlantic Ocean.

The company told Bloomberg that it’s in the early stages of researching vaccines to protect against hantaviruses. The research predates the recent outbreak and has been done alongside the US Army Medical Research Institute of Infectious Diseases and the Vaccine Innovation Center at Korea University College of Medicine, per Bloomberg.

The company shot up nearly 12% on Friday, and has risen another ~8% in early trading on Monday.

Hantavirus — which is passed by rodents and has a fatality rate of up to 50%, according to the World Health Organization — has brought back memories of the early Covid-19 days in 2020, when outbreaks surged on cruise ships and eventually spread across the world.

Moderna, a small biotech tapped to quickly develop a vaccine for Covid-19, would go on to sell $18.4 billion worth of vaccines in 2021 and $19.2 billion in 2022.

The company has shifted focus to its pipeline, as its main revenue driver, the Covid-19 vaccine, has seen a decline in demand. Earlier this month, Moderna reported quarterly results that beat Wall Street estimates and raised its guidance for the year as it sees increased demand for its new vaccines outside the US.

The European Commission approved its combination vaccine for the flu and COVID-19 for adults ‌50 years and older in April, and the US Food and Drug Administration said in February that it would reconsider its stand-alone flu vaccine.

J. Edward Moreno44m

Lumentum jumps on Nasdaq-100 Index inclusion

Lumentum rose in early trading on Monday after Nasdaq announced on Friday that it would add the optics company to its benchmark index alongside some of the world’s biggest tech companies.

Lumentum makes optical components that use light, rather than traditional copper interconnects, to move data within and between servers in data centers. Its technology is increasingly seen as critical for scaling artificial intelligence capacity.

The stock rose 4.8% in premarket trading by 6 a.m. ET. Shares are up 134% since the start of the year through Friday’s close.

On May 18, it will join the Nasdaq-100 Index, which underpins millions of portfolios. It will replace CoStar Group, a real estate data company.

Lumentum Holdings Inc. to Join the Nasdaq-100 Index® Beginning May 18, 2026

The stock rose 4.8% in premarket trading by 6 a.m. ET. Shares are up 134% since the start of the year through Friday’s close.

On May 18, it will join the Nasdaq-100 Index, which underpins millions of portfolios. It will replace CoStar Group, a real estate data company.

Robinhood traders bought the dip — and that one, that one, and that one

Everyone wants to know what Robinhood traders are doing. Subscribe to EntryPoint to find out.

David Crowther, Luke Kawa2h

Tasha Matsumoto

5/8/26

Stocks close at new records, led by chip stocks, as April jobs report surprises to upside

Stocks posted their sixth consecutive weekly gain as April payrolls quelled economic fears.

UNITED STATES - JUNE 12: Basketball: finals, Closeup of Chicago Bulls Michael Jordan victorious with wife Juanita and trophy after game vs Los Angeles Lakers, Los Angeles, CA 6/12/1991

Paige Oamek5/8/26

Akamai climbs to highest level since 2000 after reportedly securing Anthropic as a customer

Akamai’s billion-dollar AI infrastructure customer is Anthropic, Bloomberg reported on Friday. The cloud services company extended gains to trade up over 25% following the news.

On Thursday, the company announced a seven-year, $1.8 billion commitment from a “leading frontier model provider.”

Anthropic has been on a mad scramble to boost compute capacity after facing widespread complaints about Claude usage limits and seeing OpenAI position its accumulation of computing power as a competitive advantage.

In a little over a month, Anthropic has struck or expanded deals with CoreWeave, Amazon, Google, Broadcom, as well as xAI (through SpaceX).

As part of that xAI pact, Anthropic announced that it would be increasing usage limits for paying customers.

Akamai Technologies jumps on $1.8 billion cloud infrastructure deal

In a little over a month, Anthropic has struck or expanded deals with CoreWeave, Amazon, Google, Broadcom, as well as xAI (through SpaceX).

As part of that xAI pact, Anthropic announced that it would be increasing usage limits for paying customers.

Helena Cheng5/8/26

NuScale Power falls on disappointing drop in Q1 sales

NuScale shares are dropping in the early trading session after it released Q1 earnings yesterday after the bell that are failing to rejuvenate any excitement in the once high-flying, early-stage nuclear energy company.

The company announced Q1 revenue of just $560,000, well below the $10.5 million estimate, with sales down materially year over year thanks to old licensing and design deals that have since been completed.

The lack of financial progress has made NuScale Power more of a momentum-driven way to play the intersection of clean energy and AI infrastructure, particularly as hyperscalers and data center operators search for long-term power sources.

“The demand for reliable, carbon-free power has never been greater, and NuScale is the only SMR technology provider with a U.S. Nuclear Regulatory Commission approved design, an established supply chain and NPM components currently in production for commercial use to meet this essential need,” said John Hopkins, NuScale president and CEO. “We are building the infrastructure that this pivotal moment requires.”

Analysts at Goldman Sachs trimmed their price target to $9 from $10 in the wake of this report.

The company ended this quarter with cash, cash equivalents, and short- and long-term investments of $1.0 billion. The stock has dropped more than 25% year to date.